Emergent BioSolutions Inc.

NYSE:EBS

Biotechnology

Healthcare
$5.50 -2.58%

-$0.21 today

Market cap
$282.78M
Beta
2.33
P/E (TTM)
-47.9
EPS (TTM)
-$0.17
52W Low $5.62High $14.06

Volume 0.82M

Average 0.78M

EBS EBITDA Margin

EBITDA as a percentage of revenue.

Emergent BioSolutions Inc.NYSE: EBS

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to 31.1%

EBITDA Margin was 31.1% in Q1 FY2026, down 29.0 pp from a year earlier. On a trailing-twelve-month basis it was 22.8%, up 10.3 pp year over year. Over 3 fiscal years it widened by 31.0 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 2 analysts of 27.2% for the fiscal year ending Dec 2026, down from 32.4% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
31.1%+39.5 pp QoQ
Last fiscal yearDec 2025
32.4%+27.2 pp YoY
LTMMar 2026
22.8%+10.3 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-29.0 pp+1.2 pp+30.1 pp
1 year+27.2 pp-5.2 pp-32.4 pp
3 years+31.0 pp+6.7 pp-24.3 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
32.4%
Year-over-year change
+27.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How EBS compares with its peers on the latest reported figures

  • EBS's LTM Mar 2026 EBITDA Margin of 22.8% is the 3rd highest of the 8 companies compared; the peer median is 7.3%.
  • Its year-over-year change of +10.3 pp is the 4th highest of 8, against a peer median of +8.1 pp.
  • Over three fiscal years its change of +31.0 pp compares with a peer median of +4.2 pp.
EBS Competitors Peer median
EBITDA Margin for EBS and competitors
Company Period LTM level YoY 3-year change
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202643.8% +19.9 pp+89.5 pp
SIGASIGA Technologies, Inc.LTM Mar 202629.3% -22.9 pp-7.6 pp
EBSEmergent BioSolutions Inc.LTM Mar 202622.8% +10.3 pp+31.0 pp
ESPREsperion Therapeutics, Inc.LTM Mar 20269.5% +43.6 pp+249.5 pp
ORGOOrganogenesis Holdings Inc.LTM Mar 20267.3% +8.1 pp+4.2 pp
SNDLSNDL Inc.LTM Mar 20265.3% +10.5 pp+50.9 pp
AQSTAquestive Therapeutics, Inc.LTM Mar 2026-102.7% -35.0 pp-65.4 pp
PRTAProthena Corporation plcLTM Mar 2026-129.0% -45.6 pp-1804.0 pp
CMPSCOMPASS Pathways plcFY2025— ——
CRVSCorvus Pharmaceuticals, Inc.FY2025— ——
OLMAOlema Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding EBS) 7.3%+8.1 pp+4.2 pp

Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.77B1.12B1.05B1.04B742.9M
Cost of Revenue980.4M644.5M689.3M668.2M392.3M
Gross Profit793.2M473M360M375.4M350.6M
Gross Margin44.7%42.3%34.3%36.0%47.2%
Research & Development235.2M188.3M111.4M70.7M53.8M
Selling, General & Admin348.7M339.5M356.7M298.7M186.6M
Operating Expenses451.8M643M1.09B484.1M240.4M
Depreciation & Amortization118.2M125M121.1M105.6M98.3M
EBITDA504.2M15.7M(47M)53.4M240.4M
EBITDA Margin28.4%1.4%-4.5%5.1%32.4%
Operating Income341.4M(170M)(726.4M)(108.7M)110.2M
Operating Margin19.2%-15.2%-69.2%-10.4%14.8%
Interest Income00000
Interest Expense34.5M37.3M87.9M71M59.3M
Other Income / Expenses(38.2M)(49M)(4.8M)(34.2M)(27.4M)
Income Before Tax303.2M(219M)(731.2M)(142.9M)82.8M
Pre-Tax Margin17.1%-19.6%-69.7%-13.7%11.1%
Income Tax Expense83.7M(7.4M)29.3M47.7M30.2M
Net Income219.5M(211.6M)(760.5M)(190.6M)52.6M
Net Margin12.4%-18.9%-72.5%-18.3%7.1%
EPS (Basic)4.10(4.22)(14.85)(3.60)0.98
EPS (Diluted)4.06(4.22)(14.85)(3.60)0.93
Weighted Avg Shares53.5M50.1M51.2M53M53.5M
Weighted Avg Shares (Diluted)54.1M50.1M51.2M53M56.7M

Emergent BioSolutions Inc.

NYSE:EBS

Intrinsic Alpha fair value

Locked

Current Price

$5.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.